ChromaDex Corporation (CDXC): Price and Financial Metrics

ChromaDex Corporation (CDXC): $1.21

-0.08 (-6.20%)

POWR Rating

Component Grades













Add CDXC to Watchlist
Sign Up

Industry: Chemicals



in industry


  • CDXC scores best on the Quality dimension, with a Quality rank ahead of 72.62% of US stocks.
  • CDXC's strongest trending metric is Momentum; it's been moving down over the last 178 days.
  • CDXC's current lowest rank is in the Momentum metric (where it is better than 6.84% of US stocks).

CDXC Stock Summary

  • CHROMADEX CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 85.11% of US listed stocks.
  • For CDXC, its debt to operating expenses ratio is greater than that reported by only 11.99% of US equities we're observing.
  • The volatility of CHROMADEX CORP's share price is greater than that of 81.56% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHROMADEX CORP are OTLY, SMTI, INMD, PLAG, and HNST.
  • Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to

CDXC Valuation Summary

  • In comparison to the median Healthcare stock, CDXC's price/sales ratio is 36.36% lower, now standing at 1.4.
  • CDXC's price/earnings ratio has moved down 0.4 over the prior 162 months.

Below are key valuation metrics over time for CDXC.

Stock Date P/S P/B P/E EV/EBIT
CDXC 2022-09-09 1.4 4.7 -3.5 -3.6
CDXC 2022-09-08 1.4 4.7 -3.5 -3.6
CDXC 2022-09-07 1.4 4.7 -3.5 -3.6
CDXC 2022-09-06 1.4 4.6 -3.4 -3.5
CDXC 2022-09-02 1.4 4.6 -3.4 -3.6
CDXC 2022-09-01 1.4 4.7 -3.4 -3.6

CDXC Growth Metrics

    Its year over year revenue growth rate is now at 17.5%.
  • Its 5 year price growth rate is now at 71.33%.
  • Its 3 year price growth rate is now at -65.4%.
CDXC's revenue has moved up $26,789,000 over the prior 33 months.

The table below shows CDXC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 69.058 -21.893 -28.318
2022-03-31 70.025 -25.956 -27.487
2021-12-31 67.449 -24.163 -27.128
2021-09-30 65.135 -19.197 -27.9
2021-06-30 62.007 -17.123 -23.259
2021-03-31 59.595 -10.784 -21.404

CDXC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXC has a Quality Grade of C, ranking ahead of 67.33% of graded US stocks.
  • CDXC's asset turnover comes in at 1.115 -- ranking 18th of 682 Pharmaceutical Products stocks.
  • MYGN, REPH, and ENDP are the stocks whose asset turnover ratios are most correlated with CDXC.

The table below shows CDXC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.115 0.615 -3.082
2021-06-30 1.178 0.612 -2.751
2021-03-31 1.276 0.607 -3.100
2020-12-31 1.545 0.595 -2.616
2020-09-30 1.466 0.586 -2.883
2020-06-30 1.361 0.577 -2.841

CDXC Price Target

For more insight on analysts targets of CDXC, see our CDXC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.80 Average Broker Recommendation 1.3 (Strong Buy)

CDXC Stock Price Chart Interactive Chart >

Price chart for CDXC

CDXC Price/Volume Stats

Current price $1.21 52-week high $6.98
Prev. close $1.29 52-week low $1.21
Day low $1.21 Volume 158,600
Day high $1.29 Avg. volume 448,803
50-day MA $1.62 Dividend yield N/A
200-day MA $2.29 Market Cap 82.70M

ChromaDex Corporation (CDXC) Company Bio

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.

CDXC Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream

Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

LOS ANGELES, September 19, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia’s largest expo on natural health and nutrition products, with over 100,000 distributors and retailers. It is considered the best platform to help global manufacturers of health food and nutrition promote their

Yahoo | September 19, 2022

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

LOS ANGELES, September 01, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen®, is the world’s most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Br

Yahoo | September 1, 2022

This Analyst Cuts ChromaDex's Price Target On Revised Growth Trajectory

Earlier this month, ChromaDex Corp (NASDAQ: CDXC) released Q2 earnings, indicating high single-digit revenue growth for FY22, driven by its global e-commerce business, offset by slower growth with new and existing partners. For FY22, the company expects approximately 60% gross margin, while selling and marketing expenses should be down as a percentage of net sales. ChromaDex also expects to report a roughly $1 million Y/Y increase in R&D and approximately a $6-7 million decrease in G&A expense,

Yahoo | August 29, 2022

ChromaDex founder takes helm at Ginkgo Bioworks spinout

Just under a year after launching, a 'nutraceuticals' startup spun out of Ginkgo Bioworks Holdings Inc. has its first CEO.

Yahoo | August 24, 2022

Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).

Yahoo | August 24, 2022

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -18.24%
3-mo -34.95%
6-mo -53.82%
1-year -81.24%
3-year -70.70%
5-year -73.98%
YTD -67.65%
2021 -22.08%
2020 11.37%
2019 25.66%
2018 -41.67%
2017 77.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8136 seconds.